Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas
Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas
- Disease:Gastroenteropancreatic neuroendocrine tumour diseaseNeuroendocrine tumour of the lung
- Substances:AtezolizumabDacarbazine+9
France- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Intergroupe Francophone De Cancerologie Thoracique







